Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer (NCT05318469) (2026)

Government Record · Yuan Yuan (Cedars-Sinai); collaborators Agenus Inc., Gateway for Cancer Research · October 30, 2026

Yuan Yuan (Cedars-Sinai) et al., 2026-10-30: Registered phase I/II trial of ivermectin with balstilimab or pembrolizumab in metastatic triple-negative and HR+/HER2- breast cancer; RECRUITING with 34 participants estimated and no results posted.

Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week).

Yuan Yuan (Cedars-Sinai) et al., 2026-10-30: Registered phase I/II trial of ivermectin with balstilimab or pembrolizumab in metastatic triple-negative and HR+/HER2- breast cancer; RECRUITING with 34 participants estimated and no results posted. C1 record field (transcribed from the ClinicalTrials.gov API JSON; the human /study/ page is JS-rendered). Interventional, phases PHASE1/PHASE2, enrollment 34 estimated, start 2023-10-13 (actual), primary completion 2026-10 estimated, last update 2026-10-30. Arms: balstilimab 450 mg or pembrolizumab 200 mg IV day 1 q21d plus ivermectin PO days 1-3, 8-10, 15-17. Internal inconsistency in the record: the intervention entry says 'Balstilimab 300 mg' while the arm description says 450 mg. Registered, no results posted. Sponsor named as 'Yuan Yuan' (OTHER); collaborators Agenus Inc. and Gateway for Cancer Research. Also filed as IVF-19 (claims C1, C3). Study type: regulatory record.